Fertility and Sterility
Volume 87, Issue 2 , Pages 329-334 , February 2007

Increased pregnancy rate with use of the Clearblue Easy Fertility Monitor⁎

  • Janet E. Robinson, F.I.B.S.

      Affiliations

    • Family Health International, Research Triangle Park, North Carolina (formerly Unipath Diagnostics Inc., Waltham, Massachusetts)
    • ,
  • Melanie Wakelin, C.Stat.

      Affiliations

    • Wakelin Statistical Services, Bishops Stortford, Hertfordshire, United Kingdom
    • ,
  • Jayne E. Ellis, Ph.D.

      Affiliations

    • Unipath Ltd., Bedfordshire, Bedford, United Kingdom
    • Corresponding Author InformationReprint requests: Jayne E. Ellis, Ph.D., Unipath Ltd, Priory Business Park, Bedford MK44 3UP, United Kingdom (FAX: 01234-835009).

Received 28 November 2005 ,Revised 17 May 2006 ,Accepted 17 May 2006.

References 

  1. Stanford JB, White GL, Hatasaka H. Timing intercourse to achieve pregnancy: current evidence. Obstet Gynecol. 2002;100:1333–1341
  2. Wilcox AJ, Dunson D, Baird DD. The timing of the “fertile window” in the menstrual cycle: day specific estimates from a prospective study. Br Med J. 2000;321:1259–1262
  3. Eichner SF, Timpe EM. Urinary-based ovulation and pregnancy: point-of-care testing. Ann Pharmacother. 2004;38:325–331
  4. Branch CM, Collins PO, Collins WP. Ovulation prediction: changes in the concentrations of urinary estrone-3-glucuronide, estradiol-17 beta-glucuronide and estriol-16 alpha-glucuronide during conceptional cycles. J Steroid Biochem. 1982;16:345–347
  5. Adlercreutz H, Brown J, Collins W, Goebelsman U, Kellie A, Campbell H, et al. The measurement of urinary steroid glucuronides as indices of the fertile period in women (World Health Organization, Task Force on Methods for the Determination of the Fertile Period, special programme of research, development and research training in human reproduction). J Steroid Biochem. 1982;17:695–702
  6. Behre HM, Kuhlage J, Gassner C, Sonntag B, Schem C, Schneider HP, et al. Prediction of ovulation by urinary hormone measurements with the home use ClearPlan Fertility Monitor: comparison with transvaginal ultrasound scans and serum hormone measurements. Hum Reprod. 2000;15:2478–2482
  7. Tanabe K, Susumu N, Hand K, Nishii K, Ishikawa I, Nozawa S. Prediction of the potentially fertile period by urinary hormone measurements using a new home-use monitor: comparison with laboratory analyses. Hum Reprod. 2001;16:1619–1624
  8. May K. Home monitoring with the ClearPlan Easy Fertility Monitor for fertility awareness. J Int Med Res. 2001;29(Suppl 1):14A–20A
  9. Spieler J, Collins W. Potential fertility—defining the window of opportunity. J Int Med Res. 2001;29(Suppl 1):3A–13A
  10. Royston P, Ferreira A. A new approach to modelling daily probabilities of conception. Biometrics. 1999;55:1005–1013
  11. Dunson DB, Baird DD, Wilcox AJ, Weinberg CR. Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation. Hum Reprod. 1999;14:1835–1839
  12. Frank-Herrmann P, Gnoth C, Baur S, Strowitzki T, Freundl G. Determination of the fertile window: reproductive competence of women—European cycle databases. Gynecol Endocrinol. 2005;20:305–312
  13. MacGregor EA, Frith A, Ellis J, Aspinall L. Predicting menstrual migraine with a home-use fertility monitor. Neurology. 2005;64:561–563
  14. Ghazeeri GS, Vongprachanh P, Kutteh WH. The predictive value of five different urinary LH kits in detecting the LH surge in regularly menstruating women. Int J Fertil Womens Med. 2000;45:321–326
  15. Isaksson R, Tiitinen A. Present concept of unexplained infertility. Gynecol Endocrinol. 2004;18:278–290
  16. Severy LJ, Robinson J, Findley-Klein C, McNulty J. Acceptability of a home monitor used to aid in conception: psychosocial factors and couple dynamics. Contraception. 2006;73:65–71
  17. Gnoth C, Godehardt E, Frank-Herrmann P, Friol K, Tigges J, Freundl G. Definition and prevalence of subfertility and infertility. Hum Reprod. 2005;20:1144–1147
  18. NICE Clinical Guideline 11. Fertility: assessment and treatment for people with fertility problems. London: National Institute for Health and Clinical Excellence; 2004;:7

 Supported by Unipath Ltd., Bedford, United Kingdom (a division of Inverness Medical Innovations, Waltham, Massachusetts). J.E.R. and M.W. have received consulting fees from Unipath Ltd.

PII: S0015-0282(06)03093-7

doi: 10.1016/j.fertnstert.2006.05.054

Fertility and Sterility
Volume 87, Issue 2 , Pages 329-334 , February 2007

Article Tools

* Image Usage & Resolution